Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023

Download as PDF

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2022, before the US markets open on Monday, March 6, 2023. Following the announcement, the Company will host a live webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.

The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/12439. Call in information is as follows: (800)-319-4610 (US or Canada) or +1 (416)-915-3239 (International and additional options available HERE). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2021, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Investor Relations
Juli P. Miller, Ph.D., VP of Corporate Affairs and Investor Relations
M: +1 215 460 8920 
Juli.Miller@adaptimmune.com

Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217 
Dana.Lynch@adaptimmune.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/155735

SOURCE Adaptimmune Therapeutics PLC

Released February 22, 2023